MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehv104

Медицинская библиотека · European heart journal · 2015

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.

Aradi Dániel, Kirtane Ajay, Bonello Laurent, Gurbel Paul A, Tantry Udaya S, Huber Kurt, Freynhofer Matthias K, ten Berg Jurrien, Janssen Paul, Angiolillo Dominick J, Siller-Matula Jolanta M, Marcucci Rossella, Patti Giuseppe, Mangiacapra Fabio, Valgimigli Marco, Morel Olivier, Palmerini Tullio, Price Matthew J, Cuisset Thomas, Kastrati Adnan, Stone Gregg W, Sibbing Dirk

СтатьяПоддержка исследования: вне правительства СШАОбзорПеревод пока не подготовлен

Аннотация

AIMS: Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices.

METHODS AND

RESULTS

Authors of studies published before January 2015, reporting associations between platelet reactivity, ST, and major bleeding were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet function assays. Based on best available evidence for each device (exploratory studies), LPR-OPR-HPR categories were defined as <95, 95-208, and >208 PRU for VerifyNow, <19, 19-46, and >46 U for the Multiplate analyser and <16, 16-50, and >50% for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97% were treated with clopidogrel and 3% with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio (RR) and 95% CI: 2.73 (2.03-3.69), P < 0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71-0.99), P = 0.04] compared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47-2.06), P < 0.00001], without any further benefit in ST [RR: 1.06 (0.68-1.65), P = 0.78] in contrast to OPR. Mortality was significantly higher in patients with HPR compared with other categories (P < 0.05). Validation cohorts (n = 14) confirmed all results of exploratory studies (n = 3).

CONCLUSIONS

Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).

Для цитирования: Aradi Dániel, Kirtane Ajay, Bonello Laurent, Gurbel Paul A, Tantry Udaya S, Huber Kurt, Freynhofer Matthias K, ten Berg Jurrien, Janssen Paul, Angiolillo Dominick J, Siller-Matula Jolanta M, Marcucci Rossella, Patti Giuseppe, Mangiacapra Fabio, Valgimigli Marco, Morel Olivier, Palmerini Tullio, Price Matthew J, Cuisset Thomas, Kastrati Adnan, Stone Gregg W, Sibbing Dirk. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.. European heart journal. 2015. DOI: 10.1093/eurheartj/ehv104.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.